A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
Clinical trial NCT07725939 · RECRUITING
Trial details
- NCT number
- NCT07725939
- Sponsor
- UCB Biopharma SRL
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-27
- Primary completion
- 2029-06-29
- Enrollment
- 402
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.